These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
386 related articles for article (PubMed ID: 24484241)
1. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. Kline JA; Nordenholz KE; Courtney DM; Kabrhel C; Jones AE; Rondina MT; Diercks DB; Klinger JR; Hernandez J J Thromb Haemost; 2014 Apr; 12(4):459-68. PubMed ID: 24484241 [TBL] [Abstract][Full Text] [Related]
2. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Becattini C; Agnelli G; Salvi A; Grifoni S; Pancaldi LG; Enea I; Balsemin F; Campanini M; Ghirarduzzi A; Casazza F; Thromb Res; 2010 Mar; 125(3):e82-6. PubMed ID: 19833379 [TBL] [Abstract][Full Text] [Related]
3. Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes. Kline JA; Hernandez J; Hogg MM; Jones AE; Courtney DM; Kabrhel C; Nordenholz KE; Diercks DB; Rondina MT; Klinger JR Emerg Med Australas; 2013 Dec; 25(6):515-26. PubMed ID: 24224521 [TBL] [Abstract][Full Text] [Related]
4. Fibrinolysis for patients with intermediate-risk pulmonary embolism. Meyer G; Vicaut E; Danays T; Agnelli G; Becattini C; Beyer-Westendorf J; Bluhmki E; Bouvaist H; Brenner B; Couturaud F; Dellas C; Empen K; Franca A; Galiè N; Geibel A; Goldhaber SZ; Jimenez D; Kozak M; Kupatt C; Kucher N; Lang IM; Lankeit M; Meneveau N; Pacouret G; Palazzini M; Petris A; Pruszczyk P; Rugolotto M; Salvi A; Schellong S; Sebbane M; Sobkowicz B; Stefanovic BS; Thiele H; Torbicki A; Verschuren F; Konstantinides SV; N Engl J Med; 2014 Apr; 370(15):1402-11. PubMed ID: 24716681 [TBL] [Abstract][Full Text] [Related]
5. Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. Konstantinides SV; Vicaut E; Danays T; Becattini C; Bertoletti L; Beyer-Westendorf J; Bouvaist H; Couturaud F; Dellas C; Duerschmied D; Empen K; Ferrari E; Galiè N; Jiménez D; Kostrubiec M; Kozak M; Kupatt C; Lang IM; Lankeit M; Meneveau N; Palazzini M; Pruszczyk P; Rugolotto M; Salvi A; Sanchez O; Schellong S; Sobkowicz B; Meyer G J Am Coll Cardiol; 2017 Mar; 69(12):1536-1544. PubMed ID: 28335835 [TBL] [Abstract][Full Text] [Related]
6. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Steering Committee Am Heart J; 2012 Jan; 163(1):33-38.e1. PubMed ID: 22172434 [TBL] [Abstract][Full Text] [Related]
7. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. Konstantinides S; Geibel A; Heusel G; Heinrich F; Kasper W; N Engl J Med; 2002 Oct; 347(15):1143-50. PubMed ID: 12374874 [TBL] [Abstract][Full Text] [Related]
8. Comparative Efficacy and Safety of Thrombolytic Agents for Pulmonary Embolism: A Bayesian Network Meta-Analysis. Li HY; Wang YB; Ren XY; Wang J; Wang HS; Jin YH Pharmacology; 2023; 108(2):111-126. PubMed ID: 36603558 [TBL] [Abstract][Full Text] [Related]
9. Systemic Thrombolytic Therapy for Massive and Submassive Pulmonary Embolism. Igneri LA; Hammer JM J Pharm Pract; 2020 Feb; 33(1):74-89. PubMed ID: 29673293 [TBL] [Abstract][Full Text] [Related]
10. Tenecteplase for the treatment of massive and submassive pulmonary embolism. Melzer C; Richter C; Rogalla P; Borges AC; Theres H; Baumann G; Laule M J Thromb Thrombolysis; 2004 Aug; 18(1):47-50. PubMed ID: 15744554 [TBL] [Abstract][Full Text] [Related]
11. Comparison of acute and convalescent biomarkers of inflammation in patients with acute pulmonary embolism treated with systemic fibrinolysis vs. placebo. Stewart LK; Nordenholz KE; Courtney M; Kabrhel C; Jones AE; Rondina MT; Diercks DB; Klinger JR; Kline JA Blood Coagul Fibrinolysis; 2017 Dec; 28(8):675-680. PubMed ID: 28957940 [TBL] [Abstract][Full Text] [Related]
12. Contribution of fibrinolysis to the physical component summary of the SF-36 after acute submassive pulmonary embolism. Stewart LK; Peitz GW; Nordenholz KE; Courtney DM; Kabrhel C; Jones AE; Rondina MT; Diercks DB; Klinger JR; Kline JA J Thromb Thrombolysis; 2015 Aug; 40(2):161-6. PubMed ID: 25433511 [TBL] [Abstract][Full Text] [Related]
13. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. Piazza G; Hohlfelder B; Jaff MR; Ouriel K; Engelhardt TC; Sterling KM; Jones NJ; Gurley JC; Bhatheja R; Kennedy RJ; Goswami N; Natarajan K; Rundback J; Sadiq IR; Liu SK; Bhalla N; Raja ML; Weinstock BS; Cynamon J; Elmasri FF; Garcia MJ; Kumar M; Ayerdi J; Soukas P; Kuo W; Liu PY; Goldhaber SZ; JACC Cardiovasc Interv; 2015 Aug; 8(10):1382-1392. PubMed ID: 26315743 [TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Kline JA; Steuerwald MT; Marchick MR; Hernandez-Nino J; Rose GA Chest; 2009 Nov; 136(5):1202-1210. PubMed ID: 19542256 [TBL] [Abstract][Full Text] [Related]